Halozyme Therapeutics reported $46.61M in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
DBV Technologies DBVT:US -18513000 4.87M
Acadia Pharmaceuticals ACAD:US $ -33.14M 79.36M
Agios Pharmaceuticals AGIO:US $ -95.35M 3.32M
Alnylam Pharmaceuticals ALNY:US $ -181.59M 44.32M
Amarin AMRN:US $ -36.84M 9.31M
Amgen AMGN:US $ 3004M 337M
Aptinyx Inc APTX:US $ -17005000 2.27M
Baxter International BAX:US $ 787M 124M
Cara Therapeutics CARA:US $ -4409000 23.44M
Cytokinetics CYTK:US $ -9.47M 67.05M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
Esperion Therapeutics ESPR:US $ -52226000 9.39M
Halozyme Therapeutics HALO:US $ 46.61M 29.84M
Intercept Pharmaceuticals ICPT:US $ -10.87M 0.98M
Intra Cellular Therapies ITCI:US $ -87.75M 15.26M
JAZZ PHA JAZZ:US $ 282.55M 15.29M
Mannkind MNKD:US $ -23.55M 1.63M
Minerva Neurosciences NERV:US $ -6.96M 1.02M
Nektar Therapeutics NKTR:US $ -44.27M 67.08M
Peregrine Pharmaceuticals PPHM:US $ 4.34M 1.85M
Pfizer PFE:US $ 12921M 1739M
United Therapeutics UTHR:US $ 214.5M 86M